-
CSR Summary Not Yet Available
-
NCT00650806
-
Primary Citation
-
Data Specification Not Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameCanagliflozinProduct NameINVOKANA®Therapeutic AreaNutritional and Metabolic DiseasesEnrollment376% Female86%% White83%
Product ClassSodium-Glucose Co-Transporter 2 (SGLT2) InhibitorSponsor Protocol Number28431754OBE2001Data PartnerJohnson & JohnsonCondition StudiedObesityMean/Median Age (Years)44.8
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
Approved Data Requests Associated with this Trial
- 2024-0972 : Estimating Reliable Treatment Effects Despite Blinding Failures in Clinical Trials
- 2024-0580 : Developing approaches to accelerate clinical trials using real world data (RWD) from electronic health records (EHR)
- 2020-4319 : Subtype-dependent risk of stroke following the use of SGLT2 inhibitors